Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
Phase 3
Completed
- Conditions
- Attention Deficit Disorder
- Registration Number
- NCT00048360
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
Not provided
Exclusion Criteria
- Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
- Patient has a current diagnosis of Major Depressive Disorder (MDD).
- Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
- Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
- Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method ADHD Rating Scale
- Secondary Outcome Measures
Name Time Method Clinical Global Impressions -Severity and Improvement. Quality of Life Enjoyment and Satisfaction Questionnaire.
Trial Locations
- Locations (1)
GSK Clinical Trials Call Center
🇺🇸Seattle, Washington, United States